Exhibitions and Events

Add company into catalog:

Login: 
Password: 


  Registration / Why register?

Nanotechnology next Nanotechnology Exhibitions and Events

10th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems



Organizer: Renaldo Howell


10th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems

Event Opening Date:  13. March 2017

Event Termination Date:  15. March 2017

Where:
London, UK

Conference Series LLC is a renowned organization that organizes highly notable pharmaceutical conferences throughout the globe. After a successful conference of Pharmaceutica 2016, Conference Series LLC is currently bringing forth "10th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems" (Pharmaceutica 2017) slated on March 13-15, 2017 at London, UK. The conference invites all the participants across the globe to attend and share their insights and convey recent developments in the field of Pharmaceutics and Novel Drug Delivery Systems. 2017 Highlights: 300+ Participation (70% Industry: 30% Academia) 5+ Keynote Speakers 50+ Plenary Speakers 20+ Exhibitors 14 Innovative Educational Sessions 5+ Workshops B2B Meetings Exhibition: Why exhibit? Make sales Debut new products Profile your brand Meet new business partners and suppliers Develop key relationships Educate healthcare, pharma and biotech institutions and academia Who you will meet? Leaders in: Drug Delivery Formulation Drug Development Nanotechnology QbD Delivery Devices Bioavailability New Products Pre-Formulation Process R&D CMC Stability Bio manufacturing Manufacturing Solid State Chemistry Analytical Development Product Enhancement Who should sponsor? Analytical Services Formulation Development CMO Drug Delivery Technologies Full service CRO Preformulation testing Software Why you should attend? Get to the heart of why formulation and delivery strategies fail. Dissect the challenges before looking for concrete solutions. Discover how advances in the sector are impacting both large and small molecule drugs. Explore tried and tested routes to improve bioavailability. Understand how to develop the right formulation and delivery strategy with a strong scientific, clinical and commercial mind set. Discover the latest innovations in drug delivery devices. Be inspired by innovative case studies and realise the potential impact on your formulation or delivery processes. Engage in the exciting event format, with round tables, panels, showcases, speed networking and multiple conference tracks. Share experiences, insights and strategies in interactive peer-to peer round tables. Hear more perspectives in one place – from large medium and small organisations from pharma, biotech and academia. Discover how scientific formulation advancements are being implemented in practice. Get to the heart of why formulation and delivery strategies fail. Dissect the challenges before looking for concrete solutions.

Conference Series LLC is a renowned organization that organizes highly notable pharmaceutical conferences throughout the globe. After a successful conference of Pharmaceutica 2016, Conference Series LLC is currently bringing forth "10th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems" (Pharmaceutica 2017) slated on March 13-15, 2017 at London, UK.

Pharmaceutica 2017 covers various aspects of Pre-formulation Considerations, Formulation Aspects for Various Routes, Recent Advances in Drug Delivery Technology, Drug Targeting, Nanotechnology in Drug Delivery Systems and its Application, Major Challenges in Drug Delivery System, Physiological Considerations, Vaccine Drug Delivery Systems, Drug Discovery and Development, Medical Devices for Drug Delivery, Smart Drug Delivery Systems, Delivery Methods for Peptides and Biologics, Global Drug Policy in Drug Delivery Technology.

Track-1: Pre-Formulation & Formulation Aspects

Pharmaceutics is the study of relationships between preformulation, pharmaceutical formulation, delivery, disposition and clinical response. The inherent instability nature of a new drug will alter its desired form into undesired form when presented in a suitable dosage form with the excipient/s upon storage. In early days this process was confined only for assessing few characteristics, but today this process is being considered as a formulation strategy and hence tremendous technological advancement has been achieved in this field which enables us to save time and money through planned management system and hence impacts Pharmaceutica 2017 to be a formulation conference. Use of glorious statistical software even based on artificial neural networking are made the task of preformulation and optimization process easier. Role of preformulation studies techniques like freeze drying aspects projects the event Pharmaceutica 2017 to pose as a freeze drying meeting in drug discovery, drug development plays major role in pharmaceutical formulation development and the studies will help in different dosage forms design. With the increasing number of novel and specialized compounds being developed, a "one size fits all" approach to drug formulation and delivery is no longer optimal, necessitating the consideration of formulations unique to each drug. NDDS conference will discuss on Early Approaches, Present Scenario and Future Prospects of Preformulation events. There are more than 1400 sustained or controlled release drugs have been approved all over the world. Pharmaceutical conferences discuss the state-of-art technology being applied and involve advances in formulation studies.

Revenues within the global generics market reached an estimated value of $265 b in 2012, showing a growth of 9.3% throughout the year. The contribution of generics is approximately 20% of overall international pharmaceutical market. The utilization of generic in terms of volume is higher in the US and lower in Japan, 89% and 24% respectively.

Track-2: Pharmacokinetics and Pharmacodynamics in Drugs

Pharmacokinetics is currently defined as the study of the time course of drug absorption, distribution, metabolism, and excretion. Clinical pharmacokinetics is the application of pharmacokinetic principles to the safe and effective therapeutic management of drugs in an individual patient. Primary goals of clinical pharmacokinetics include enhancing efficacy and decreasing toxicity of a patient’s drug therapy. The development of strong correlations between drug concentrations and their pharmacologic responses has enabled clinicians to apply pharmacokinetic principles to actual patient situations.

Pharmacodynamics refers to the relationship between drug concentration at the site of action and the resulting effect, including the time course and intensity of therapeutic and adverse effects. The effect of a drug present at the site of action is determined by that drug’s binding with a receptor. Receptors may be present on neurons in the central nervous system (i.e., opiate receptors) to depress pain sensation, on cardiac muscle to affect the intensity of contraction, or even within bacteria to disrupt maintenance of the bacterial cell wall.

Track-3: Computer-Aided Drug Design (CADD)

The most fundamental goal in drug design is to predict whether a given molecule will bind to a target and if so how strongly. Molecular mechanics or molecular dynamics are most often used to predict the conformation of the small molecule and to model conformational changes in the biological target that may occur when the small molecule binds to it. Semi-empirical, ab initio quantum chemistry methods, or density functional theory are often used to provide optimized parameters for the molecular mechanics calculations and also provide an estimate of the electronic properties (electrostatic potential, polarizability, etc.) of the drug candidate that will influence binding affinity.

Molecular mechanics methods may also be used to provide semi-quantitative prediction of the binding affinity. Also, knowledge-based scoring function may be used to provide binding affinity estimates. These methods use linear regression, machine learning, neural nets or other statistical techniques to derive predictive binding affinity equations by fitting experimental affinities to computationally derived interaction energies between the small molecule and the target.

Ideally, the computational method will be able to predict affinity before a compound is synthesized and hence in theory only one compound needs to be synthesized, saving enormous time and cost. The reality is that present computational methods are imperfect and provide, at best, only qualitatively accurate estimates of affinity. In practice it still takes several iterations of design, synthesis, and testing before an optimal drug is discovered. Computational methods have accelerated discovery by reducing the number of iterations required and have often provided novel structures.

Track-4: Routes of Drug Delivery

A route of administration is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration. Routes can also be classified based on where the target of action is. Action may be topical (local), enteral (system-wide effect, but delivered through the gastrointestinal tract), or parenteral (systemic action, but delivered by routes other than the GI tract).

Routes of administration are usually classified by application location (or exposition). The route or course the active substance takes from application location to the location where it has its target effect is usually rather a matter of pharmacokinetics (concerning the processes of uptake, distribution, and elimination of drugs). Nevertheless, some routes, especially the transdermal or transmucosal routes are commonly referred to routes of administration. The location of the target effect of active substances is usually rather a matter of pharmacodynamics (concerning e.g. the physiological effects of drugs). Furthermore, there is also a classification of routes of administration that basically distinguishes whether the effect is local (in "topical" administration) or systemic (in "enteral" or "parenteral" administration).

Track-5: Nanoparticulate Drug Delivery Systems

Nanoparticles (NPs) occur naturally and have been in existence for thousands of years as products of combustion and cooking of food. Nanomaterials differ significantly from other materials due to the following two major principal factors: the increased surface area and quantum effects. These factors can enhance properties such as reactivity, strength, electrical characteristics, and in vivo behaviour. As the particle size decreases, a greater proportion of atoms are found at the surface compared to inside. An NP has a much greater surface area per unit mass compared with larger particles, leading to greater reactivity. In tandem with surface area effects, quantum effects can begin to dominate the properties of matter as size is reduced to the nanoscale. These can affect the optical, electrical, and magnetic behaviour of materials. Their in vivo behaviour can be from increased absorption to high toxicity of nanomaterials. New drug carrier systems are one can name soluble polymers, microparticles made of insoluble (or) biodegradable natural and synthetic polymers, microcapsules, cells, cell ghosts, lipoproteins, liposomes and micelles. Pharmaceutica 2017 evolves to be a drug disintegration conference, emulsion conference, capsule conference, and solubility conference. Pharmaceutical conferences will cover industry case studies, regulatory updates, latest therapies and technology innovations and much more.

Key players in the market include Amgen, Inc., AstraZeneca plc, Eli Lilly & Co., Ipsen S.A., Merck & Co., Novartis AG, Novo Nordisk A/S, Roche Holdings AG, Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Limited. Leading API manufacturers include Bachem Holding AG, PolyPeptide Group, and Peptisyntha Inc. at the pharmaceutical companies’ conference.

The global market for blood-brain barrier (BBB) technology for therapeutics reached $21.8 million in 2013. This market is expected to grow from $38.7 million in 2014 to $471.5 million in 2019, a compound annual growth rate (CAGR) of 64.9% from 2014 through 2019.

Track-6: Nanotechnology in Drug Delivery

Nanotechnology has finally and firmly entered the realm of drug delivery. Performances of intelligent drug delivery systems are continuously improved with the purpose to maximize therapeutic activity and to minimize undesirable side-effects. The primary goals for research of nano-bio-technologies in drug delivery include:

  • More specific drug targeting and delivery,
  • Reduction in toxicity while maintaining therapeutic effects,
  • Greater safety and biocompatibility, and
  • Faster development of new safe medicines

Pharmaceutical conferences offers presentations by researchers from a number of disciplines, from the life sciences to engineering, who will address a range of topics including peptide and protein delivery, gene delivery, cell delivery, vaccines, transdermals, pulmonary delivery, new materials, and other subjects, from varied disciplines while focusing on the central theme of drug delivery.

Key players in the market include Amgen, Inc., AstraZeneca plc, Eli Lilly & Co., Ipsen S.A., Merck & Co., Novartis AG, Novo Nordisk A/S, Roche Holdings AG, Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Limited. Leading API manufacturers include Bachem Holding AG, PolyPeptide Group, Peptisyntha Inc. and Lonza Inc.

The global market for blood-brain barrier (BBB) technology for therapeutics reached $21.8 million in 2013. This market is expected to grow from $38.7 million in 2014 to $471.5 million in 2019, a compound annual growth rate (CAGR) of 64.9% from 2014 through 2019.

Track-7: Pharmaceutical Nanotechnology

Size reduction is a fundamental unit operation having important applications in pharmacy. It helps in improving solubility and bioavailability, reducing toxicity, enhancing release and providing better formulation opportunities for drugs. In most of the cases, size reduction is limited to micron size range, for example, various pharmaceutical dosage forms like powder, emulsion, suspension etc. Drugs in the nanometer size range enhance performance in a variety of dosage forms. Major advantages of nanosizing include (i) increased surface area, (ii) enhanced solubility, (iii) increased rate of dissolution, (iv) increased oral bioavailability, (v) more rapid onset of therapeutic action, (vi) less amount of dose required, (vii) decreased fed/fasted variability, and (viii) decreased patient-to-patient variability.

Pharmaceutical nanotechnology has provided more fine-tuned diagnosis and focused treatment of disease at a molecular level. Pharmaceutical nanotechnology is most innovative and highly specialized field, which will revolutionize the pharmaceutical industry in near future. Pharmaceutical nanotechnology presents revolutionary opportunities to fight against many diseases. It helps in detecting the antigen associated with diseases such as cancer, diabetes mellitus, neurodegenerative diseases, as well as detecting the microorganisms and viruses associated with infections. It is expected that in next 10 years market will be flooded with nanotechnology devised medicine.

Track-8: Smart Drug Delivery Systems

Smart drug delivery is a method of delivering medication to a patient in a manner that increases the concentration of the medication in some parts of the body relative to others. This means of delivery is largely founded on nanomedicine, which plans to employ nanoparticle-mediated drug delivery in order to combat the downfalls of conventional drug delivery. These nanoparticles would be loaded with drugs and targeted to specific parts of the body where there is solely diseased tissue, thereby avoiding interaction with healthy tissue. The goal of a targeted drug delivery system is to prolong, localize, target and have a protected drug interaction with the diseased tissue. The conventional drug delivery system is the absorption of the drug across a biological membrane, whereas the targeted release system releases the drug in a dosage form. The advantages to the targeted release system is the reduction in the frequency of the dosages taken by the patient, having a more uniform effect of the drug, reduction of drug side-effects, and reduced fluctuation in circulating drug levels. The disadvantage of the system is high cost, which makes productivity more difficult and the reduced ability to adjust the dosages.

Targeted drug delivery systems have been developed to optimize regenerative techniques. The system is based on a method that delivers a certain amount of a therapeutic agent for a prolonged period of time to a targeted diseased area within the body. This helps maintain the required plasma and tissue drug levels in the body, thereby preventing any damage to the healthy tissue via the drug. The drug delivery system is highly integrated and requires various disciplines, such as chemists, biologists, and engineers, to join forces to optimize this system.

The global revenue for advanced drug delivery systems is estimated to be $151.3 billion in 2013. In 2018, revenues are estimated to reach nearly $173.8 billion, demonstrating a compound annual growth rate (CAGR) of 2.8%.

Track-9: Biomaterials in Drug Delivery

Biomaterials are any substance that has been engineered to interact with biological systems for a medical purpose - either a therapeutic (treat, augment, repair or replace a tissue function of the body) or a diagnostic one. Biomaterials can be derived either from nature or synthesized in the laboratory using a variety of chemical approaches utilizing metallic components, polymers, ceramics or composite materials. They are often used and/or adapted for a medical application, and thus comprise whole or part of a living structure or biomedical device which performs, augments, or replaces a natural function. Such functions may be benign, like being used for a heart valve, or may be bioactive with a more interactive functionality such as hydroxy-apatite coated hip implants. Biomaterials are also used every day in dental applications, surgery, and drug delivery. For example, a construct with impregnated pharmaceutical products can be placed into the body, which permits the prolonged release of a drug over an extended period of time. A biomaterial may also be an autograft, allograft or xenograft used as a transplant material. Pharmaceutica 2017 have penetrated into the biomaterials realm and hence a biomaterials conference.

Global revenue for vaccine technologies was nearly $31.8 billion in 2011. This market is expected to increase from $33.6 billion in 2012 to $43.4 billion in 2017 at a compound annual growth rate (CAGR) of 5.3%.

Track-10: Vaccine Drug Delivery Systems

Vaccine is a material that induces an immunologically mediated resistance to a disease but not necessarily an infection. Vaccines are generally composed of killed or attenuated organisms or subunits of organisms or DNA encoding antigenic proteins of pathogens. Sub-unit vaccines though exceptionally selective and specific in reacting with antibodies often fail to show such reactions in circumstances such as shifts in epitopic identification center of antibody and are poorly immunogenic. Delivery of antigens from oil-based adjuvants such as Freunds adjuvant lead to a reduction in the number of doses of vaccine to be administered but due to toxicity concerns like inductions of granulomas at the injection site, such adjuvants are not widely used. FDA approved adjuvants for human uses are aluminium hydroxide and aluminium phosphate in the form of alum. Hence, search for safer and potent adjuvants resulted in the formulation of antigen into delivery systems that administer antigen in particulate form rather than solution form.

Track-11: Medical Devices for Drug Delivery

A medical device is any instrument, apparatus, appliance, software, material or other article, whether used alone or in combination, including the software intended by its manufacturer to be used specifically for diagnostic and/or therapeutic purposes and necessary for its proper application, intended by the manufacturer to be used for human beings for the purpose of:

  • Diagnosis, prevention, monitoring, treatment or alleviation of disease;
  • Diagnosis, monitoring, treatment, alleviation of or compensation for an injury or handicap;
  • Investigation, replacement or modification of the anatomy or of a physiological process;
  • Medical devices vary according to their intended use and indications. Examples range from simple devices such as tongue depressors, medical thermometers, and disposable gloves to advanced devices such as computers which assist in the conduct of medical testing, implants, and prostheses. The design of medical devices constitutes a major segment of the field of mechanical engineering. Pharmaceutica 2017 is considered to be a medical devices conference.

The drug-device combination market is not fragmented and the key players in this market are Medtronic, Boston Scientific Corp., Edwards Life sciences Corp., Stryker Corp., QLT Inc. etc. The maximum number of new product developments is expected to take place in the bone graft substitutes, advanced wound care products and antimicrobial catheter markets. Our patent analysis indicates that E.U. has filed for the maximum number of patents followed by the U.S.

Track-12: Peptides and Protein Drug Delivery

Peptides and proteins have great potential as therapeutics. Peptides can be designed to target a broad range of molecules, giving them almost limitless possibilities in fields such as oncology, immunology, infectious disease and endocrinology. While the peptide and protein therapeutic market has developed significantly in the past decades, delivery has limited their use. Although oral delivery is preferred, most are currently delivered intravenously or subcutaneously due to degradation and limited absorption in the gastrointestinal tract. Therefore, absorption enhancers, enzyme inhibitors, carrier systems and stability enhancers are being studied to facilitate oral peptide delivery. Additionally, transdermal peptide delivery avoids the issues of the gastrointestinal tract, but also faces absorption limitations. Due to proteases, opsonization and agglutination, free peptides are not systemically stable without modifications.

Currently, the market for peptide and protein drugs is estimated to be greater than US$40 billion/year, or 10% of the pharmaceutical market. This market is growing much faster than that of small molecules, and will make up an even larger proportion of the market in the future. At present there are over 100 approved peptide-based therapeutic drugs on the market, with the majority being smaller than 20 amino acids. Compared with the typical small-molecule drugs that currently make up the majority of the pharmaceutical market, peptides and proteins can be highly selective as they have multiple points of contact with their target. Increased selectivity may also result in decreased side effects and toxicity.

Major drugs driving growth of the overall smart drug delivery market include Angiomax, Copaxone, Forteo, Sandostatin, Velcade, Victoza and Zoladex.

Track-13: Global Drug Delivery Policy

The global market for Business Development of Drug Delivery Technology in 2010 was $131.6 billion and is expected to rise at a compound annual growth rate (CAGR) of 5% and reach nearly $175.6 billion by 2016. The U.S. constituted approximately 59% of the total drug delivery market in 2010 and was $78 billion. It is forecast to reach nearly $103 billion in 2016 at a CAGR of 4.7%. Europe contributed about 27% of the total drug delivery market in 2010 and was $36 billion and is expected to grow to $49 billion by 2016 at a CAGR of 5.6% for 2013, Drug Delivery Global market reached $150.3 billion, according to BCC research. This was an increase from $142 billion the previous year. Given its predicted annual growth the market represents a considerable business opportunity, which has been reflected in the increasing number of drug delivery specialists.

Consistent quality and competitive costs of product improves Production performance and continuity of supply and Product and technology auditing and due diligence with minimizing Regulatory Issues, quality control, and business development Business opportunities in drug delivery. Pharmaceutical conferences offer unparalleled opportunities to establish new business relationships with companies from 40 countries through pre-scheduled one-on-one meetings with decision makers.


Next Nanotechnology Events


TOPlist